Advanced Search
MyIDEAS: Login

Karl Philip Claxton

Contents:

This is information that was supplied by Karl Claxton in registering through RePEc. If you are Karl Philip Claxton , you may change this information at the RePEc Author Service. Or if you are not registered and would like to be listed as well, register at the RePEc Author Service. When you register or update your RePEc registration, you may identify the papers and articles you have authored.

Personal Details

First Name: Karl
Middle Name: Philip
Last Name: Claxton
Suffix:

RePEc Short-ID: pcl81

Email: [This author has chosen not to make the email address public]
Homepage: http://www.york.ac.uk/che/staff/research/karl-claxton/
Postal Address:
Phone:

Affiliation

Centre for Health Economics
Department of Economics and Related Studies
University of York
Location: York, United Kingdom
Homepage: http://www.york.ac.uk/inst/che/
Email:
Phone: (01904) 321401
Fax: (0)1904 323759
Postal: York Y010 5DD
Handle: RePEc:edi:chyoruk (more details at EDIRC)

Works

as in new window

Working papers

  1. Karl Claxton & Simon Walker & Steven Palmer & Mark Sculpher, 2010. "Appropriate Perspectives for Health Care Decisions," Working Papers 054cherp, Centre for Health Economics, University of York.
  2. Mike Paulden & Karl Claxton, 2009. "Budget allocation and the revealed social rate of time preference for health," Working Papers 053cherp, Centre for Health Economics, University of York.
  3. Stefano Conti & Karl Claxton, 2008. "Dimensions of design space: a decision-theoretic approach to optimal research design," Working Papers 038cherp, Centre for Health Economics, University of York.
  4. Claire McKenna & Zaid Chalabi & David Epstein & Karl Claxton, 2008. "Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions," Working Papers 044cherp, Centre for Health Economics, University of York.
  5. McCabe, C & Claxton, K & Culyer, AJ, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," MPRA Paper 26466, University Library of Munich, Germany.
  6. Karl Claxton & Mark Sculpher & Tony Culyer, 2007. "Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions," Working Papers 031cherp, Centre for Health Economics, University of York.
  7. Laura Bojke & Karl Claxton & Stephen Palmer & Mark Sculpher, 2006. "Defining and characterising structural uncertainty in decision analytic models," Working Papers 009cherp, Centre for Health Economics, University of York.
  8. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2005. "The value of implementation and the value of information: combined and uneven development," Working Papers 005cherp, Centre for Health Economics, University of York.
  9. Karl Claxton & Simon Eggington & Laura Ginnelly & Susan Griffin & Christopher McCabe & Zoe Philips & Paul Tappenden & Alan Wailoo, 2005. "A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence," Working Papers 004cherp, Centre for Health Economics, University of York.
  10. Elizabeth Fenwick & Karl Claxton & Mark Sculpher & Andrew Briggs, 2000. "Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling," Working Papers 179chedp, Centre for Health Economics, University of York.
  11. Carlos Lerner & Karl Claxton, 1994. "Modelling the behaviour of general practitioners: a theoretical foundation for studies of fundholding," Working Papers 116chedp, Centre for Health Economics, University of York.
  12. K. Claxton & P. J. Neumannn & S. S. Araki & M. C. Weinstein, . "Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's Disease," Discussion Papers 00/39, Department of Economics, University of York.
  13. Karl Claxton & John Posnett, . "The Role of Decision Analysis in Structuring the Economic Evaluation of Sequential Clinical Decision Problems," Discussion Papers 96/24, Department of Economics, University of York.
  14. Karl Claxton & John Posnett, . "An Economic Approach to Clinical Trial Design and Research Priority Setting," Discussion Papers 96/19, Department of Economics, University of York.
  15. Carlos Lerner & Karl Claxton, . "Effects of Fundholding on the Prescribing and Referral Behavior of General Practitioners," Discussion Papers 96/9, Department of Economics, University of York.

Articles

  1. Karl Claxton & Mike Paulden & Hugh Gravelle & Werner Brouwer & Anthony J. Culyer, 2011. "Discounting and decision making in the economic evaluation of health‐care technologies," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 2-15, January.
  2. McKenna, Claire & Chalabi, Zaid & Epstein, David & Claxton, Karl, 2010. "Budgetary policies and available actions: A generalisation of decision rules for allocation and research decisions," Journal of Health Economics, Elsevier, vol. 29(1), pages 170-181, January.
  3. Mark Sculpher & Karl Claxton, 2010. "Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1132-1136.
  4. Weatherly, Helen & Drummond, Michael & Claxton, Karl & Cookson, Richard & Ferguson, Brian & Godfrey, Christine & Rice, Nigel & Sculpher, Mark & Sowden, Amanda, 2009. "Methods for assessing the cost-effectiveness of public health interventions: Key challenges and recommendations," Health Policy, Elsevier, vol. 93(2-3), pages 85-92, December.
  5. Karl Claxton, 2008. "Exploring Uncertainty in Cost-Effectiveness Analysis," PharmacoEconomics, Springer Healthcare | Adis, vol. 26(9), pages 781-798.
  6. Chalabi, Zaid & Epstein, David & McKenna, Claire & Claxton, Karl, 2008. "Uncertainty and value of information when allocating resources within and between healthcare programmes," European Journal of Operational Research, Elsevier, vol. 191(2), pages 530-539, December.
  7. Christopher McCabe & Karl Claxton & Anthony J. Culyer, 2008. "The NICE Cost-Effectiveness Threshold: What it is and What that Means," PharmacoEconomics, Springer Healthcare | Adis, vol. 26(9), pages 733-744.
  8. Karl Claxton, 2007. "Oft, Vbp: Qed?," Health Economics, John Wiley & Sons, Ltd., vol. 16(6), pages 545-558.
  9. Claxton, Karl, 2007. "In recognition of Anthony J. Culyer," Journal of Health Economics, Elsevier, vol. 26(6), pages 1073-1074, December.
  10. Mark J. Sculpher & Karl Claxton & Mike Drummond & Chris McCabe, 2006. "Whither trial-based economic evaluation for health care decision making?," Health Economics, John Wiley & Sons, Ltd., vol. 15(7), pages 677-687.
  11. A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381.
  12. Cynthia P. Iglesias & Karl Claxton, 2006. "Comprehensive Decision-Analytic Model and Bayesian Value-of-Information Analysis: Pentoxifylline in the Treatment of Chronic Venous Leg Ulcers," PharmacoEconomics, Springer Healthcare | Adis, vol. 24(5), pages 465-478.
  13. Karl P. Claxton & Mark J. Sculpher, 2006. "Using Value of Information Analysis to Prioritise Health Research: Some Lessons from Recent UK Experience," PharmacoEconomics, Springer Healthcare | Adis, vol. 24(11), pages 1055-1068.
  14. Zoe Philips & Laura Bojke & Mark Sculpher & Karl Claxton & Su Golder, 2006. "Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment: A Review and Consolidation of Quality Assessment," PharmacoEconomics, Springer Healthcare | Adis, vol. 24(4), pages 355-371.
  15. Karl Claxton & Mark Sculpher & Anthony Culyer & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier, 2006. "Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion," Health Economics, John Wiley & Sons, Ltd., vol. 15(1), pages 1-4.
  16. Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347.
  17. Anthony O'Hagan & Christopher McCabe & Ron Akehurst & Alan Brennan & Andrew Briggs & Karl Claxton & Elisabeth Fenwick & Dennis Fryback & Mark Sculpher & David Spiegelhalter & Andrew Willan, 2005. "Incorporation of Uncertainty in Health Economic Modelling Studies," PharmacoEconomics, Springer Healthcare | Adis, vol. 23(6), pages 529-536.
  18. Anthony O'Hagan & Christopher McCabe & Ron Akehurst & Alan Brennan & Andrew Briggs & Karl Claxton & Elisabeth Fenwick & Dennis Fryback & Mark Sculpher & David Spiegelhalter & Andrew Willan, 2005. "The Authors' Reply," PharmacoEconomics, Springer Healthcare | Adis, vol. 23(8), pages 853.
  19. John Brazier & Ron Akehurst & Alan Brennan & Paul Dolan & Karl Claxton & Chris McCabe & Mark Sculpher & Aki Tsuchyia, 2005. "Should Patients Have a Greater Role in Valuing Health States?," Applied Health Economics and Health Policy, Springer Healthcare | Adis, vol. 4(4), pages 201-208.
  20. Laura Ginnelly & Karl Claxton & Mark J. Sculpher & Sue Golder, 2005. "Using Value of Information Analysis to Inform Publicly Funded Research Priorities," Applied Health Economics and Health Policy, Springer Healthcare | Adis, vol. 4(1), pages 37-46.
  21. Claxton, K. & Thompson, K. M., 2001. "A dynamic programming approach to the efficient design of clinical trials," Journal of Health Economics, Elsevier, vol. 20(5), pages 797-822, September.
  22. Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost-effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787.
  23. Mark Sculpher & Elisabeth Fenwick & Karl Claxton, 2000. "Assessing Quality in Decision Analytic Cost-Effectiveness Models: A Suggested Framework and Example of Application," PharmacoEconomics, Springer Healthcare | Adis, vol. 17(5), pages 461-477.
  24. Karl Claxton & Larry F. Lacey & Stephen G. Walker, 2000. "Selecting treatments: a decision theoretic approach," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 163(2), pages 211-225.
  25. Karl Claxton, 1999. "Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 269-274.
  26. Bryan R. Luce & Karl Claxton, 1999. "Redefining the analytical approach to pharmacoeconomics," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 187-189.
  27. Claxton, Karl, 1999. "The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies," Journal of Health Economics, Elsevier, vol. 18(3), pages 341-364, June.

Editor

  1. Journal of Health Economics, Elsevier.

NEP Fields

5 papers by this author were announced in NEP, and specifically in the following field reports (number of papers):
  1. NEP-HEA: Health Economics (2) 2008-02-16 2010-04-17. Author is listed

Statistics

Most cited item

Most downloaded item (past 12 months)

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Karl Claxton should log into the RePEc Author Service

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.